A Phase 4 interventional study of Metformin and Dapagliflozin/Pioglitazone in Type 2 Diabetes, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 4, Interventional, and Treatment
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's planned enrollment of 204 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Boryung Pharmaceutical Co., Ltd is the lead sponsor of 139 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
One tablet of Metformin and one tablet of Dapagliflozin 10mg/Pioglitazone 30mg administered orally once daily for 24 weeks.
Drug: Metformin · Drug: Dapagliflozin/Pioglitazone
One tablet of Metformin and one tablet of Dapagliflozin 10mg/Sitagliptin 100mg administered orally once daily for 24 weeks.
Drug: Metformin · Drug: Dapagliflozin/Sitagliptin
The dosage and dose frequency are maintained as they were before the screening.
Dapagliflozin 10mg/Pioglitazone 30mg QD
Dapagliflozin 10mg/Sitagliptin 100mg QD
HbA1c (%) change at 24 weeks compared to the baseline (Visit 2)
The mean change of HbA1c at 24 weeks compared to the baseline (Visit 2) is evaluated.
Time frame: From baseline to end of treatment at 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd